| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
Purity: =98.70%
| Targets |
Natural flavone
|
|---|---|
| ln Vitro |
In a dose-dependent manner, cirsilineol (0.1-10 μM; 96) suppresses Concanava A-induced T cell proliferation as well as single mixed hour responses. T's activity is unaffected by cirsilineol (10 μM). IFN-γ-induced Tyr701 phosphorylated STAT1 and JAK2 activation is totally inhibited by Cirsilineol (10 μM) compared to T Cirsilineol (1–10 μM; inhibition for 3 hours) [1].Cytotoxic activity is not the cause of the reduction of cell proliferation[1].
|
| ln Vivo |
By blocking IFN-γ/STAT1/T-bet signaling in CD4+ T cells, cirsilineol (3, 10, and 30 mg/kg) dramatically reduced TNBS-induced Th1-mediated cardiovascular inflammation.
|
| Cell Assay |
Cell Proliferation Assay[1] Inhibition of cell proliferation is not due to cytotoxic activity[1].
Cell Types: Splenocytes Tested Concentrations: 0.1, 1, 10 μM Incubation Duration: 96 hrs (hours) Experimental Results: Inhibition of single mixed lymphocyte reaction and concanavalin A (Con A; 5 μg/mL; for 72 hrs (hours)) induction in a dose-dependent manner of T cell proliferation. Inhibits the proliferation of OVA323-339-specific CD4+ T cells. Western Blot Analysis[1] Cell Types: Splenic CD4+ T cells Tested Concentrations: 1, 5, 10 μM Incubation Duration: 3 hrs (hours) of pretreatment Experimental Results: Complete inhibition of IFN-γ-induced (25 ng; 30 minutes) Tyr701 phosphorylation of STAT1 and JAK2 activation. Inhibits IFN-γ induction (25 ng; 12 hrs (hours)) of the Th1-specific transcription factor T-bet. |
| Animal Protocol |
Animal/Disease Models: 8-10 weeks old female C57BL/6, BALB/c and DO11.10 transgenic mice using TNBS (10 mg; 100 μL) [1]
Doses: 3, 10, 30 mg/kg Route of Administration: IP; daily; 11 days Experimental Results: Dramatically improved the body weight and survival rate of mice. Dramatically reduces inflammatory infiltration, restores destructive mucosal structure and relieves edema. |
| References | |
| Additional Infomation |
Cirsilineol is a trimethoxyflavone that is flavone substituted by methoxy groups at positions 6, 7 and 3' and hydroxy groups at positions 5 and 4' respectively. It has a role as a plant metabolite and an antineoplastic agent. It is a trimethoxyflavone and a dihydroxyflavone. It is functionally related to a flavone.
Cirsilineol has been reported in Ajania fastigiata, Salvia officinalis, and other organisms with data available. See also: Tangerine peel (part of). |
| Molecular Formula |
C18H16O7
|
|---|---|
| Molecular Weight |
344.3154
|
| Exact Mass |
344.09
|
| Elemental Analysis |
C, 62.79; H, 4.68; O, 32.53
|
| CAS # |
41365-32-6
|
| PubChem CID |
162464
|
| Appearance |
Typically exists as White to light yellow solids at room temperature
|
| Density |
1.387g/cm3
|
| Boiling Point |
585ºC at 760 mmHg
|
| Flash Point |
215.2ºC
|
| Index of Refraction |
1.627
|
| LogP |
2.897
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
520
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(=C([H])C(C2=C(C(=C(C([H])=C12)OC([H])([H])[H])OC([H])([H])[H])O[H])=O)C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])O[H]
|
| InChi Key |
VKOSQMWSWLZQPA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O7/c1-22-13-6-9(4-5-10(13)19)12-7-11(20)16-14(25-12)8-15(23-2)18(24-3)17(16)21/h4-8,19,21H,1-3H3
|
| Chemical Name |
5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-6,7-dimethoxychromen-4-one
|
| Synonyms |
Eupatrin; Fastigenin; Anisomelin; 4',5-Dihydroxy-3',6,7-trimethoxyflavone; Cirsileneol; 4,5-Dihydroxy-3,6,7-trimethoxyflavone;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL | |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL | |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA